Technique of platelet-rich plasma lyophilisation with preserving tgf pdgf vegf factor viability

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, enabling preparing a biologically active preparation of autoblood for enhancing neogenesis processes. The presented technique involves sampling whole blood, centrifuging, selecting a middle layer of plasma so that to avoid the erythrocyte ingress. The centrifuged platelet concentrate is frozen in a cold room at temperature below minus 1 C°, dried for at least three minutes within the temperature range of 2 C° to 52 C°; the lyophilisate is sterilised before use.

EFFECT: technique of platelet-rich plasma lyophilisation enables preserving the TGF PDGF VEGF factor viability min 1,5 months from the moment of blood sampling.

1 tbl


The invention relates to medicine, namely to traumatology and orthopedics, allows to produce biologically active preparation of autologous blood to accelerate tissue regeneration processes of the organism.

Known technology of preparation and use of platelet-rich plasma (PRP) stimulates regeneration of living tissues (Robert E. Marx Platelet-reach plasma (PRP): what is PRP and what is not PRP? // Implant dentistry, Vol.10 No.4 2001). PRP is obtained by centrifugation of whole blood with subsequent selection of a layer of plasma over useprofanity erythrocytes with a concentration of platelets at least 1 million/µl.

Known growth factors - polypeptides with molecular weight of 5-50 kDa, with a wide spectrum of biological actions. The growth factors, as a rule, are produced by specialized cells, including platelets. These include transforming growth factor (TGF), platelet-derived growth factor (PDGF), vascularendothelial growth factor (VEGF). TGF inhibits the synthesis of inflammatory cytokines, increases the synthesis of proteins of the extracellular matrix, promotes healing, and has anabolic effect and stimulates fibroblasts, the development of the endothelium, is involved in regulation of cell proliferation. PDGF is involved in regulation of acute inflammation, wound healing and scarring (found:

In the available literature, the discussion is about the activity of these factors in living tissues or immediately after separation from cells and/or tissues, but have not found information about saving activity after freezing and subsequent drying of serum.

A well-known drug, which is a concentrate of platelet growth factors and the method of their preparation (WO/2009/087560 from 16.07.2009; PCT/IB2009/000013 GWO REI). The product is intended for therapeutic and/or cosmetic use, contains the growth factors PDGF, TGF-β, IGF, EGF, CTGF, bFGF and VEGF. A method of obtaining a concentrate of platelet growth factors in accordance with the invention includes a stage of contacting the platelet concentrate with the solvent and/or surface-active substances, incubation of platelets with the solvent and/or surface-active substances for a period of not less than 5 minutes to 6 hours. Acidity (pH) is maintained in the range from about 6.0 to about 9.0 to, and at a temperature in the range from 2°C to 50°C, preferably in the range from 25°C to 45°C.

The disadvantages of the method: to obtain growth factors requires the use of other active substances that are not desirable for introduction into the patient's body, which can cause allergic reactions. There is no information about the possibility of long-term storage obtained by this technology is the AI of the growth factors PDGF, TGF-β, IGF, EGF, CTGF, bFGF and VEGF.

Known application JP 2011120763 MATERIAL FOR REGENERATION TREATMENT 23.06.2011; A61L 15/16; 2009281382. The development is aimed at obtaining materials for tissue regeneration using platelet-rich plasma and does not require preparation before use or cryopreservation. The material for the regeneration treatment contains platelet-rich plasma, frozen and dried. The material is applied on a solid surface tools for osteosynthesis, use after storage in the refrigerator at least one day, freezing and drying. Material for regeneration can be used after platelet-rich plasma was stored in the refrigerator for at least thirty days after freezing and drying. Tools for osteosynthesis can be selected from the group of textiles, porous materials, granular materials, foams. For structural modeling solid support can be made from biodegradable materials, coated with a ligand of a cellular receptor substrate adhesion prior to application of platelet-rich plasma.

The disadvantages of the method: no information about the degree of preservation of growth factors after freezing and drying of the platelet-rich plasma.

Technical result: development of technology lyophilizate the platelet-rich plasma, you can save the vitality factors such as PDGF TGF VEGF. A distinctive feature of this technology is the lack of exposure to chemical agents for the release of growth factors from platelets,

For the implementation of the methods produce intake of whole blood in an amount of about three times larger than diagnosed objective methods the volume of living tissue defect. In sterile tubes with observance of the rules of asepsis trying to enter the blood, after adding an anticoagulant, such as citrate, heparin, or any other. After filling the tubes with the blood of it is covered with a sterile tube and carefully, gently, overturn several times to mix the anticoagulant and blood. Next, the blood is subjected to centrifugation speed 1000-1200 rpm at least three minutes under conditions of hypothermia in the temperature range from 0C° to 6C°. Under sterile conditions make the selection of the middle layer of the plasma in such a way as to prevent the ingress of erythrocytes. Obtained by centrifugation of the platelet concentrate is a viscous liquid straw yellow color with platelets of about 800 thousand per microliter. Further, the concentrate is frozen in the refrigerator at a temperature lower than minus 1C°.

Frozen platelet concentrate is subjected to dry aniu for at least three minutes in the temperature range from 2C° to 52C°. Obtained by drying the freeze-dried is placed in an airtight container, store in dry conditions. Before applying the lyophilisate is subjected to sterilization, for example, ozone treatment or irradiation with gamma rays.

Before applying sterile lyophilisate shape corresponding to the tissue defect, if the substitution is subject to the bone, or put on a bandage for application to a wound on the body surface, or metal, designed for osteosynthesis or other auxiliary structures and materials intended for tissue regeneration. Possible breeding in solutions intended for dissolution of drugs with the purpose of injecting, for example, in a physiological solution of sodium chloride, procaine. The resulting solution is injected into an area with a shortage of the regenerative processes of bone tissue.

The method was tested using nine blood samples taken from three healthy donors, three patients in burn units with thermal burn not less than 23% of the body surface; three patients ICU with multiple injuries of the musculoskeletal system as a result of road traffic accidents (RTA). The results are presented in the table.

Assessment Protocol the content of growth factors in freeze-dried platelet-rich plasma
The patient's conditionThe content of growth factors
Burn 38% of body surface4,3735973,7662343,761089
Burns 33% of body surface2,2292981,4772732,977823
Burns 29% of body surface3,3014472,6217533,369456
Multiple injuries (accidents)1,610750,3814942,599798
Multiple injuries (accidents)1,0982380,6980522,642137
Multiple injuries (accidents)1,3544940,5397732,620968

Cooked in our technology lyophilized platelet-rich plasma was used in the form of applications in the bandages for the treatment of defects of the skin tissue and injection in place of bone fractures in periods ranging from two weeks to six months from the date of blood sampling. With each patient and his relatives preliminary conversation about the essence of the method, the contract on informed consent. Wound healing occurred faster than the stipulated deadline for such amount and type of tissue damage.

The technology of preparation of freeze-dried platelet-derived growth factors allows to gain new, not known from the prior art effect: the preservation of the viability of the growth factors TGF, PDGF, VEGF from platelet-rich plasma for at least a month and a half since the blood of the patient.


Same patents:

FIELD: chemistry.

SUBSTANCE: invention can be used in chemical industry. Method of gypsum calcination includes stages at which: gypsum is introduced into reactor under pressure 27, fuel and air are burnt in burner 41 with formation of gaseous products of combustion. After that, part of gaseous products of combustion and air are supplied to reactor under pressure 27 with creation of fluidised bed of gypsum in reactor. After that, remaining part of gaseous products of combustion is directed into heat exchanger 52, which is applied for heating of fluidised bed and fluidised bed of gypsum is heated in reactor under pressure 27 for sufficient calcination of gypsum with formation of calcinated semihydrate.

EFFECT: invention makes it possible to obtain alpha-semihydrate of calcium sulfate with reduced fuel consumption.

8 dwg, 1 tbl

FIELD: process engineering.

SUBSTANCE: invention relates to conversion of organic material into product. Proposed method comprises bringing organic material in contact with supercritical fluid whereat it interacts with it to produce the product. Fluid may be heated by external heater or may be heated in-process by combined feed of oxidiser and fluid. Said oxidiser may be fed in amount preset for adjustment of reaction mix heating degree.

EFFECT: sufficient energy for activation.

25 cl, 2 dwg

FIELD: process engineering.

SUBSTANCE: invention relates to processes used in operation at high pressure and modifying substances physically. Proposed method comprises placing diamond in reaction cell in pressure transmitting medium, increasing pressure in reaction chamber and it cooling. Note here that thermal treatment is carried out at temperature increase rate of 10-50°C/s and at 2000-2350°C by passing electric current via heater in cell from programmed power supply source with due allowance for temperature relaxation in said cell in heating. For this, note also that temperature relaxation constant is defined. Said cell is cooled after heating by switching off power supply in forming short diamond heating pulse in temperature range of over 2000°C with diamond total stay time smaller than 30 seconds. Allowance for temperature relaxation in said cell in heating for heating rate Vt and pre-definition of cell temperature relaxation constant τ is made by setting in said programmable power source the maximum temperature of heating to τVT above maximum treatment temperature of 2000-2350°C.

EFFECT: changing colour of low-grate natural diamond without notable graphitisation, high-quality gem diamonds.

2 cl, 5 dwg, 3 ex

FIELD: machine building.

SUBSTANCE: window on pressure pipe includes housing located throughout the length of the pipe or at the end of pressure pipe. Diametrically opposite sides of the pipe are provided with flanges with passages oriented in radial direction. Axes of passages are perpendicular to longitudinal axis of pressure pipe and lie in the measuring plane of X-ray measuring device. X-ray emission source is located outside one passage, and receiver sensitive to X-ray emission is located outside the other passage. Window arranged on pressure pipe includes window plates permeable for X-ray emission and installed tightly in the corresponding passage and fixed in the passage by means of fasteners. Window plates consist of the material resistant to high temperatures and action of corrosive chemical process substances. The design at least of lower window plate and target maintenance of uniform temperature of window plate are made so that temperature of window plate is maintained below condensation point of gas medium in pressure pipe, and condensate can freely flow to pressure pipe.

EFFECT: reduction of corrosion of window plate and increase in its service life.

19 cl, 11 dwg

FIELD: chemistry.

SUBSTANCE: disclosed is a method of producing a conducting polymer product in form of fine particles with average size of 0.02-0.05 mcm, with improved conductivity, involving: putting a conducting polymer product, which is a product obtained via polymerisation of 3,4-ethylene dioxythiophene in aqueous solution of polystyrene sulphonic acid and/or polyaniline, water, an organic solvent which is compatible with the conducting polymer product, and carbon dioxide gas into a container operating under pressure; and exposing the medium inside the container operating under pressure to heat and pressure in order to convert carbon dioxide to a supercritical state.

EFFECT: improved conductivity of the conducting polymer product.

4 cl, 3 dwg, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the technology of the performance of electrochemical reaction processes during the subcritical and supercritical fluids transition from one phase to another and can be applied to the recycling of high-toxic substances and radioactive wastes; the method of the continuous execution of the electrochemical reaction includes the supply of the flow of the basic reagent under supercritical pressure, the electrochemical activation of the flow in the discharge zone (4) with the formation of numerous gas-vapor bubbles of the cavitation mixture, reduction of the flow velocity in the reaction zone (7), execution of the further interaction of the cavitation mixture securing collapsing of the gas-vapor bubbles with the formation of reaction mixture and throttling of the flow of the reaction mixture by means of the reducing device (10) supporting the requisite supercritical pressure in the reaction zone (7); the device for the method implementation comprises the basic reagent induct supply installment (1), the electro-discharge reactor in the shape of the cylindrical housing (3) having two interconnected reaction zones: the discharge zone (4) and reaction zone (7), the electrode (2) coaxially installed inside of the reactor connected to the power supply source (6) through the dielectric inserting element (5) and the reducing device (10).

EFFECT: invention enables to enhance the process efficiency and relative productivity.

19 cl, 1 dwg, 9 exl

FIELD: process engineering.

SUBSTANCE: invention relates to gate device comprising at least one separate gate for strip material passage. In compliance with this invention, separate gate is formed by at least one first and one second parts interconnected by split joint for separate gate to be opened and closed. There should be at least one drive to displace separate gate first and second part in direction of strip material feed or opposite it with opened joint.

EFFECT: possibility to service or repair gate device without removing strip material therefrom.

14 cl, 6 dwg

FIELD: chemistry.

SUBSTANCE: method of conducting mechanochemical reactions during compression, temperature, pressure and ultrasonic treatment of starting material in a reactor involves processing the mass with an auger. The processed mass in volume of 10-90% reversibly enters through reactor channels into a multiple compression zone and ultrasonic treatment carried out using a double-frequency annular ultrasonic concentrator the frequency of which differs from each other by 0.01-15%. The mechanochemical reactor includes a housing 1, a shaft 5 rotated by a drive, a starting material receiving container 4, an auger 2, a mouthpiece 9 and an ultrasonic generator. The reactor housing 1 is in form of a polyhedron with channels 12 along the axis of the housing 1, with combs 11 in the channels. The ultrasonic generator is an annular ultrasonic concentrator 8. The reactor enables to obtain salts of humic acids from a mixture of peat and alkali which makes up 10-20% of the weight of peat in the dry equivalent.

EFFECT: method and apparatus enable to obtain a homogenised product in a reactor in which an efficient mechanochemical reaction takes place to obtain natural ecologically clean fertiliser.

3 cl, 4 dwg, 1 ex

Strip sluice gate // 2412754

FIELD: machine building.

SUBSTANCE: invention refers to strip sluice gate for packing first space relative to second space; also, strip, particularly, metallurgical strip runs in both spaces; additionally, at least two rollers are designed for space packing; rollers adjoin strip on both ends ensuring packing. To improve packing, according to the invention, at least one roller has a packing element in its one axial end zone adjoining the end of the strip from a side. Location devices position the roller together with the packing element in axial direction.

EFFECT: mutual packing of spaces with different process mediums at different and similar pressure.

17 cl, 17 dwg

FIELD: process engineering.

SUBSTANCE: invention relates to processing of material containing solid substance by decomposition using water at subcritical parametres. Proposed method comprises feeding initial stock into reactor with its inner volume maintained at subcritical water parametres via reactor inlet pipe. Stationary layer, fluidised layer and layer of fluid containing decomposition product in water with subcritical parametres are created inside reactor. Withdrawal of fluid containing decomposition product in water with subcritical parametres is performed via any of multiple discharge pipes arranged at different distance from reactor inlet pipe that allows creating stationary flow of said fluid and regulating period of its presence inside reactor. Withdrawal of target decomposition product is performed via any discharge pipe selected from multiple outlet pipes located at the level with high concentration of target decomposition product.

EFFECT: regulation of decomposition reaction, reduced costs and selective production of target substances.

27 cl, 15 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: what is presented is a boric coating containing a barrier material and an adhesive material. The barrier material and adhesive material are applicable for combined or sequential postoperative application on the mucosal tissue. Such application provides a multilayer film dressing containing a layer of the above barrier material and a layer of the above adhesive material contacting with the barrier material and mucosal tissue. The dressing is left unmoved in place for 48 hours after the postoperative application of the multilayer film on the mucosal tissue. The dressing is absorbed for 14 days. The multilayer film dressing has an external rim surrounding a tonsil bed and a concave centre shaped after the tonsil bed.

EFFECT: reducing or eliminating pain sensations following the mucosal operations, including tonsilectomy, adenoidectomy or other pharyngeal operations.

19 cl, 17 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to dressings used in general surgery, traumatology, obstetrics, gynaecology, proctology, dentistry for closure and healing of wounds (including post-operative), bed-sores, ulcers, burns, complicated purulent and putrid infections with an evident purulo-necrotic layer. A wound and burn closure and healing dressing containing a wound or burn facing therapeutic layer consisting of a therapeutic and sorption agent that is a layer of paste-like gel of iron or aluminium gel with added graphite carbon at 1 g of the additive per 100 ml of the gel, of the thickness of 0.5 cm providing a sorption ability not less than 10 g/g.

EFFECT: preparing the wound and burn dressing possessing high antimicrobial activity and analgesic characteristics, improved sorption ability and atraumatic properties.

7 tbl, 23 dwg

Wound tissue // 2483755

FIELD: medicine.

SUBSTANCE: invention refers to medicine, to preparing a therapeutic and preventing agent for treating radioreactions accompanying the course of radiotherapy. A wound tissue contains a textile fibre-porous material with a viscose component coated with a polymer and a drug preparation introduced therein; the novel is the fact that it is suggested to use the textile material which is made of flax-viscose fibres in ratio of components of flax:viscose 40 - 70 and 60-30, respectively. The fibre-porous material is prepared by needle suturing and has area density 180 g/m2 - 260 g/m2. The coating polymer is sodium alginate, while the drug preparation is introduced in the concentration of 0.25-30 wt %. The drug preparation coating the suggested flax-viscose carrier is presented by poorly soluble preparations of Furaginum, metronidazole, 5-fluoruracil, antioxidant Mexidol, biologically active substances - propolis, sea buckthorn and blackberry extracts.

EFFECT: presented drug preparation has proved itself to be easy to use, enabling higher clinical effectiveness, increasing a prolongation time.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a sorption plate containing furacilin, differing by the fact that a process for making it involves using the additional excipient therapeutic powdered Kimmeridge clay (blue) Undorovskaya, chitosan solution, dimethylsulphoxide, glycerol, acetic acid and purified water in the following proportions (wt %): furacilin 0.75 - 1.5; dimethylsulphoxide 2.5 - 5.0; blue clay 7.5 - 8.5; 98% acetic acid 1.5 - 3.0; chitosan 2.5 - 4.5; glycerol (7.5 - 8.5); purified water up to 100.0.

EFFECT: invention provides making sorption plates for ensuring wound-healing, anti-inflammatory action in medical practice and higher sorption activity.

9 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a composition for preparing a polyurethane foam dressing which contains the ingredients in the composition in the following ratio, weight fractions: low-molecular polyesterpolyol No. 1 - 75-90, low-molecular polyesterpolyol No. 2 - 10-25, water - 1.0-2, a foaming agent - 1.0-3.0, an urethane formation catalyst - 0.05-0.3, a co-catalyst - 0.05-0, a foam regulator - 2.0-7.5, a bactericidal additive - 1.0-1.2, aromatic diisocyanate - 30-60.

EFFECT: requiring no additional fixation, the medical dressing is easily applied on a wound surface regardless of a configuration and a size of the injured area, and is formed directly on the patient's wound, providing a sterile surface and an anaesthetic effect; its open porous structure absorbs various wound discharges.

3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to method of obtaining medical napkin for treatment of wounds and burns. In method of obtaining medical napkin, which includes carrying out textile material padding in solution of medication with the following drying in the air, padding is carried out in solution of sodium alginate polysaccharide with content of 18-22% dimexide, and after drying by method of textile printing water solution of polymer composition containing 18-22% of urea, 5-7% of sodium alginate is applied on textile carrier, with following drying of processed material in the air. Method makes it possible to considerably increase concentration of medication in napkin, considerably extend spectrum of applied medications, including by low-soluble, as it does not require presence of functional groups in medication for immobilisation on functional groups of fibre.

EFFECT: method is simpler in realisation, less durative, does not require additional processing of textile material, ie more manufacturable and economical.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to a therapeutic plaster which can provide injured skin or open wounds with an active substance promoting faster or improved wound healing. The plaster shows the new design features which particularly enable drug substances containing proteins or peptides, e.g. erythropoietin (EPO) to exhibit their wound healing and stimulating action ensured by active substance release from the plaster which is not subject to substantial inactivation by the substances contained in wound secretion, and is not metabolised.

EFFECT: making the therapeutic plaster which can provide injured skin or open wounds with an active substance promoting faster or improved wound healing.

37 cl, 1 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a biodegradable plaster containing at least one bioadhesive layer, and at least one non-bioadhesive layer with the bioadhesive layer containing at least one polyarphon dispersion, and at least one bioadhesive polymer with the polyarphon dispersion containing at least one pharmacologically active substance.

EFFECT: biodegradable plaster can deliver drugs, including poorly water soluble ones.

21 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a bandage for pain region processing. The bandage provides cooling and delivery of therapeutic formulations to this region. The bandage comprises a bearing carrier, an interpenetrating network of gel-type dope of polyvinyl alcohol and a cross-linking agent wherein the interpenetrating network is located in the bearing carrier, and at least one additional therapeutic agent.

EFFECT: bandage may be applicable many times on various body parts.

21 cl, 4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a haemostatic device for blood coagulation improvement which contains a gauze base, a clay material located thereon, and also polyol, such as glycerol or similar placed on the gauze base for binding the clay material. The device for bleeding wound management comprises at least a portion of the clay material contacting to blood flowing from the wound to cause coagulation. A dressing applicable on the bleeding wound for blood coagulation improvement comprises a flexible base and a gauze base located thereon. The gauze base comprises the clay material and polyol. Ahaemostatic sponge also contains a gauze basis and a disperse system of the haemostatic material and polyol on the first base surface. The invention also refers to N-substituted monomers and polymers, methods for producing such monomers and polymers and to methods for using for various medical purposes, e.g. in medical devices. In the preferential versions, a medical device represents a stent.

EFFECT: haemostatic device improves blood coagulation.

43 cl, 1 tbl, 9 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology, pharmaceutics and medicine, more specifically to a new generation of high-stable dosage forms prepared with using the process of sublimation in a specific mode with a composition containing no stabilising agents reducing the width of therapeutic action of finished dosage form substantially. The invention concerns the pharmaceutical composition for injections and infusions containing 3-oxy- and methylpyridine derivatives and pharmaceutically acceptable salts thereof as an active ingredient, sodium chloride or potassium chloride as an additive agent, in the form a lyophilisate. The process involves the sublimation followed by the vacuum dewatering for at least 64 hours.

EFFECT: pharmaceutical composition possesses high stability for the whole shelf-life as opposed to all known pharmaceutical formulations of these compounds; it preserves pharmacological activity and enables dissolving the composition immediately before use and reducing a risk of the negative effect of the thermal sterilisation of aqueous solutions.

2 cl, 7 ex, 2 tbl